A study of 1,028 travelers vaccinated with TAK-003 in Catalonia indicates the dengue vaccine has a good safety profile for non-endemic regions. Findings published in The Lancet Regional Health Europe.
A recent study conducted by the Barcelona Institute for Global Health, in collaboration with Hospital Clínic Barcelona, has revealed that the dengue vaccine TAK-003 shows favorable safety and tolerability profiles among travelers from areas where dengue is not endemic. The research involved 1,028 individuals who received the vaccine in Catalonia.
The study aimed to assess the real-world effectiveness of the dengue vaccine in a non-endemic setting. Participants were monitored for any adverse reactions following vaccination. Key findings indicated that the vaccine was well-tolerated with no serious side effects reported. The majority of participants experienced mild or moderate symptoms, such as pain at the injection site and fever, which are common post-vaccination responses.
Dr. Maria Rodriguez, a lead researcher from the Barcelona Institute for Global Health, commented on the results: "Our findings suggest that TAK-003 is safe and well-tolerated among travelers from non-endemic regions. This is crucial information as it supports the use of the vaccine in countries where dengue is not commonly found."
The study was published in The Lancet Regional Health Europe, providing valuable insights for public health officials and travel medicine experts. These findings could pave the way for broader vaccination programs targeting travelers from non-endemic areas.
In conclusion, the favorable safety profile of TAK-003 among travelers from non-endemic regions highlights its potential as a tool to protect individuals at risk of contracting dengue during international travels. Further research and implementation strategies are needed to ensure widespread access and effectiveness in preventing dengue infections globally.
